Quercetin alleviates cell apoptosis and inflammation via the ER stress pathway in vascular endothelial cells cultured in high concentrations of glucosamine

XIAXIA CAI¹,²*, LEI BAO³*, YE DING⁴, XIAOQIAN DAI¹, ZHAOFENG ZHANG¹ and YONG LI¹

¹Department of Nutrition and Food Hygiene, School of Public Health, Peking University, Beijing 100191; ²School of Public Health, Beijing Key Laboratory of Environment Toxicology, Capital Medical University, Beijing 100069; ³Department of Clinical Nutrition, Peking University International Hospital, Beijing 100191; ⁴Department of Maternal, Child and Adolescent Health, School of Public Health, Nanjing Medical University, Nanjing, Jiangsu 211166, P.R. China

Received August 24, 2015; Accepted November 3, 2016

DOI: 10.3892/mmr.2016.6054

Abstract. Glucosamine is a possible cause of vascular endothelial injury in the initial stages of atherosclerosis, through endoplasmic reticulum (ER) stress resulting in fatty streaks in the vascular wall. Quercetin is an anti-diabetic and cardiovascular protective agent that has previously been demonstrated to reduce ER stress in human umbilical vein endothelial cells (HUVECs). The present study aimed to investigate whether quercetin prevents glucosamine-induced apoptosis and inflammation via ER stress pathway in HUVECs. The effect of quercetin on cell viability, apoptosis, and protein expression levels of inflammatory cytokines and ER stress markers was investigated in glucosamine-supplemented HUVECs. Quercetin was demonstrated to protect against glucosamine-induced apoptosis, improved cell viability, and inhibited expression of pro-inflammatory factors and endothelin-1. Quercetin treatment also reduced the expression levels of glucose-regulated protein 78, phosphorylated protein kinase-like ER kinase, phosphorylated c-Jun N-terminal kinase and C/EBP homologous protein. In conclusion, quercetin may have auxiliary therapeutic potential against glucosamine-induced cell apoptosis and inflammation, which may be partially due to alleviation of ER stress.

Introduction

Diabetes is a ‘coronary heart disease (CHD) equivalent’ disease, as epidemiological data has previously demonstrated that patients with diabetes without any prior evidence of CHD are at greater risk of death from CHD than nondiabetic patients with prior evidence of CHD (1,2). Atherosclerosis (AS) is a disease of arterial lipid deposition leading to a number of biological responses, including a chronic, macrophage-dominated inflammatory reaction (3), and is the pathological basis of CHD. The hexosamine biosynthesis pathway (HBP), a normal pathway for glucose metabolism, is activated excessively in patients with diabetes, resulting in increased cellular glucosamine (4). Endoplasmic reticulum (ER) is a membranous network to synthesize, modify, fold and assemble proteins. When the ER function, particularly folding capacity, is challenged, the unfolded protein response (UPR) is executed as a protective mechanism in ER. Failure of this mechanism to fold newly synthesized proteins shows unique damage to the cell and is termed ‘ER stress’ (5,6). Numerous studies have highlighted that ER stress may link hyperglycemia to AS (4,7,8). Important ER stress markers, including protein kinase-like ER kinase (PERK), glucose regulated protein 78 (GRP78) and C/EBP homologous protein (CHOP), were expressed in the arterial wall of streptozotocin-induced hyperglycemic apolipoprotein (apoE)-deficient mice (4). Glucosamine levels and the expression of GRP78 were increased following hyperglycemia and prior to the early stages of fatty streak formation in aortic endothelial cells of hyperglycemic apoE−/− mice (7). In vitro studies have demonstrated that incubation of hepatic cells (9) and adipocytes (10) with 5 mM glucosamine resulted in lipid accumulation, impaired insulin-stimulated glucose transport and elevated levels of ER stress markers. High-dose glucosamine may, therefore, increase the inflammatory...
response and induce lipid metabolic abnormalities, further aggravate endothelial cell injury and, ultimately, accelerate the development of AS (11). However, as an effective nutritional supplement in human osteoarthritis, orally administered glucosamine sulfate demonstrated an anti-atherosclerotic effect in rabbits with AS aggravated by chronic arthritis (12). Incubation of human umbilical vein endothelial cells (HUVECs) with 0.5 mM glucosamine has previously been demonstrated to inhibit tumor necrosis factor-α-induced inflammation (13), and glucosamine significantly suppressed mesangial cell viability at a concentration of 15 mM (14). The concentration of glucosamine that induces cell injury, and the mechanism by which ER stress leads to cell injury under conditions of high glucosamine is, therefore, unclear.

Persistent and serious ER stress causes apoptosis, which results in a series of pathophysiologically changes, including increased phosphorylation of protein kinase-like ER kinase (PERK), a trans-ER-membrane factor, which results in increased levels of C/EBP homologous protein (CHOP) (15). CHOP can induce transcriptional activation of endoplasmic reticulum oxidoreductase-1 (ERO1) and ERO1α can activate the inositol triphosphate receptor (IP3R). IP3R can subsequently stimulate excess Ca2+ transport from the ER to the mitochondria, triggering cell death (16). CHOP also can inhibit Bel-2 transcription directly to initiate apoptosis (16,17). Diabetes and AS are characterized by low-grade, chronic inflammation (11,18). Previous studies have suggested that c-Jun N-terminal kinase (JNK) linked ER stress and apoptosis, and was also the link between ER stress and inflammation (19) and insulin resistance (20). Thus, the use of anti-inflammatory and anti-apoptotic agents against inflammation, apoptosis and ER stress may contribute to the prevention of AS in patients with diabetes.

Quercetin is a widely distributed plant flavonoid, which has been reported to possess biological activities against cardiovascular disease and associated risk factors (21). Epidemiological (22) and clinical studies (23) suggest that there is an inverse correlation between flavonoid supplementation and cardiovascular risk, and numerous clinical and animal studies have reported the anti-inflammatory and anti-oxidative functions of quercetin (23-29). Furthermore, quercetin alleviates AS development in rabbits (30) and mice (31). Quercetin has also been demonstrated to control blood glucose levels, and improve glucose uptake and insulin sensitivity in vitro (32,33). Suganya et al (34) also demonstrated that quercetin prevents tunicamycin-induced ER stress through modulation of GRP78 and CHOP levels in endothelial cells. Chao et al (35) demonstrated that the inhibitory effect of 300 nM quercetin sulfate/glucuronide (the metabolite of quercetin in blood) on apoptosis and JNK activity under conditions of high glucose was similar to that of 100 µM ascorbic acid, an antioxidant commonly used to improve vascular function. However, limited research has been performed to investigate the effect of quercetin on ER stress under diabetic conditions, and the relevant mechanisms.

As vascular endothelial cell injury is the initial step of AS (36), the present study hypothesized that high levels of glucosamine, a HBP metabolite, would mimic the early stages of vascular endothelial cell injury in diabetes. The present study aimed to investigate the protective effect of quercetin on inflammation and apoptosis in HUVECs treated with high-dose glucosamine, and to determine whether this protective effect was associated with inhibition of ER stress.

Materials and methods

Reagents and antibodies. High-glucose Dulbecco's modified Eagle's medium (DMEM) and fetal bovine serum (FBS) were obtained from Gibco; Thermo Fisher Scientific, Inc. (Waltham, MA, USA). Trypsin, dimethyl sulfoxide (DMSO) and MTT were purchased from MAC GenE Technology (Beijing, China; http://maingen.com/cart/). Quercetin, (≥95%, HPLC), N-acetyl-D-glucosamine and tunicamycin (from Streptomyces spp.) were purchased from Sigma-Aldrich, Merck Millipore (Darmstadt, Germany). Endothelial cell growth supplement (ECGS; cat. no. 1052) was obtained from ScienCell Research Laboratories (Carlsbad, CA, USA). Human soluble intercellular adhesion molecule-1 (ICAM-1)/CD54 Quantikine ELISA kit (cat. no. DCD540), human soluble vascular cell adhesion molecule-1 (VCAM-1)/CD106 Quantikine ELISA kit (cat. no. DVC00) and endothelin-1 (ET-1) Quantikine ELISA kit (cat. no. DET100) were obtained from R&D Systems, Inc. (Minneapolis, MN, USA). One-step terminal-deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) apoptosis in situ detection kit was purchased from Nanjing KeyGen Biotech Co., Ltd. (Nanjing, China). Polyclonal antibody to GRP78 (cat. no. 3183) and monoclonal antibodies to CHOP (cat. no. 2895), PERK (cat. no. 5683) and β-actin (cat. no. 4970) were purchased from Cell Signaling Technology, Inc. (Danvers, MA, USA). Phosphorylated (p)-PERK (cat. no. sc-32577), JNK D-2 (cat. no. sc-7345), p-JNK G-7 (cat. no. sc-6254), VCAM-1 H276 (cat. no. sc-8304) and caspase-3 (cat. no. sc-7148) antibodies were purchased from Santa Cruz Biotechnology, Inc. (Dallas, TX, USA). Goat anti-mouse immunoglobulin G (IgG; H+L)-horseradish peroxidase (HRP; cat. no. ZB-2305), goat anti-rabbit IgG (H+L)-HRP (cat. no. ZB-2301) and goat anti-rat IgG (H+L)-HRP (cat. no. ZB-2307) antibody conjugates were obtained from OriGene Technologies, Inc. (Beijing, China).

Cell culture and treatments. HUVECs (no. CRL-1730) were obtained from the American Type Culture Collection (Manassas, VA, USA). Cells were cultured in high-glucose DMEM supplemented with 10% FBS and 0.05 mg/ml ECGS at 37°C in a humidified, 5% CO2 atmosphere. Cells were subcultured in culture flasks (Corning Incorporated, Corning, NY, USA) and passaged every 3 days. The cells were used at their fourth passage. All experiments were performed at the logarithmic phase of cell growth, and it took 24 h to grow to logarithmic phase of cell. At 70% confluence, the cells were cultured for 12 h in serum-free medium. The cells incubated in normal medium (high-glucose DMEM with 10% FBS) for 24 h were used as the vehicle group and other HUVECs in high-glucose DMEM and 10% FBS were subsequently divided into seven groups: 'HG' group cells were cultured in 15 mM glucosamine; 5, 10, 20 and 50 µM quercetin group cells were cultured in 15 mM glucosamine and various doses of quercetin (5, 10, 20 and 50 µM, respectively); mannitol group cells were cultured in 15 mM mannitol (subsequently referred to as osmolarity control); and another HUVECs were cultured...
in high-glucose DMEM and 10% FBS with 50 µM quercetin (subsequently referred to as quercetin control). The aforementioned cells were cultured for a further 24 h. In another group of experiments, the cells were treated with 5 µg/ml tunicamycin for 4 h as positive control. The concentration of quercetin used in previous *in vitro* studies into cardiovascular diseases ranged from 10-80 µM (30,35,37), while the highest concentration of quercetin observed in murine plasma was 27.6 µM (31). However, the highest concentration of quercetin observed in human plasma was 4.1 µM, which was observed 10 h after ingestion of 1.095 mg quercetin (38). Due to the limited availability of information regarding quercetin cell cytotoxicity, concentrations of 0.5, 10, 20 and 50 µM quercetin were utilized in the present study.

**MTT assay.** Cell viability was detected by MTT assay as previously described (14,39). Following treatment in 96-well plates for 24 h, 100 µl MTT (1 mg/ml) solutions was added to each well, then cells were incubated for 4 h at 37˚C. The MTT solution was then discarded, and 100 µl DMSO was added to each well. Absorbance at 490 nm was then read using a microplate reader (Bio-Rad Laboratories, Inc., Hercules, CA, USA). Values were normalized to those of cells in the vehicle group.

**TUNEL assays.** DNA fragmentation was observed by TUNEL as previously described (14). Cells were treated on cover slips in 6-well plates at a density of 3x10^5 cells/ml. Following intervention, cells were fixed in 4% paraformaldehyde for 30 min at room temperature, then washed 3 times in phosphate-buffered saline (PBS). Triton X-100 (1%) was added for 3-5 min to promote permeability, then cells were washed again in PBS. Cells were blocked with 3% H₂O₂ for 10 min at room temperature and incubated with 50 µl terminal deoxynucleotidyl transferase enzyme reaction solution (45 µl equilibration buffer, 1 µl tetramethyl rhodamine isothiocyanate-5'-dUTP and 4 µl terminal deoxynucleotidyl transferase enzyme) for 60 min at 37˚C in the dark. Fluorescence intensity was measured using an Eclipse TE2000-S fluorescence microscope (Nikon Corporation, Tokyo, Japan) using wavelengths of 543 nm (excitation) and 571 nm (detection). Red fluorescence indicated the presence of apoptotic cells. Apoptotic cells were counted in three random high-power fields (HPF) of three different slides.

**ELISA.** Following 24-h treatment in 24-well plates, concentrations of VCAM-1, ICAM-1, and ET-1 were determined by ELISA according to manufacturer's instructions (40,41). Supernatant was collected and centrifuged at 1,000 x g for 10 min. The lyophilized quantikine standard was reconstituted in distilled water and serially diluted 1:2 in kit standard diluent to produce standard curve samples. Prior to the experiment, the samples required a 5-fold dilution (a suggested 5-fold dilution is 20 µl of samples and 80 µl of Calibrator Diluent). A total of 100 µl human ICAM-1 or VCAM-1 conjugate was added to each well. Next, 100 µl standard, control (recombinant human sICAM-1 and VCAM-1 provided with the kits as positive controls) and experimental samples were added to the designated wells in a 96-well polystyrene microplate (provided with the kit). The plate was covered with the adhesive strip provided and incubated for 1.5 h at room temperature on a horizontal orbital microplate shaker (0.12” orbit). Following this, the wells were washed with 400 µl wash buffer three times. After the final wash, for ET-1, 150 µl of assay diluent was added to each well. A total of 75 µl standard, control (Synthetic Endothelin-1 provided with the kits as positive controls) and experimental samples were subsequently added to each well. The plate was covered with an adhesive strip and incubated for 1 h at room temperature on a horizontal orbital microplate shaker. The plates were washed as before four times. The plates were the incubated for 3 h at room temperature with 200 µl HRP-conjugated secondary antibody. The wells were washed, as before. Substrate solution (200 µl for ICAM-1 and ET-1, 100 µl for VCAM-1, chromogen solution A and chromogen solution B were mixed together in equal volumes) was then added to each well, and the plates were protected from light and incubated for 30 min at room temperature. Finally, 50 µl stop solution was added to the wells and the colored products were measured at 450 nm within 30 min, with the wavelength correction set at 570 nm, on a multi-detection microplate reader (Bio-Rad Laboratories, Inc.). The standard curve, experimental and control samples were assayed in duplicate.

**Western blotting.** Cells from each group were treated for 24 h in 10 mm culture dishes, and then cells (1x10⁵) were washed three times in ice-cold PBS, then lysed for 30 min in lysis buffer [20 mM Tris-HCl (pH 7.5), 150 mM NaCl, 1 mM Na₂EDTA, 1 mM EGTA, 1 mM Na₃VO₄, 11 mM β-mercaptoethanol, 0.1% Triton X-100, 2.5 mM NaPO₄, 1 µg/ml leupeptin, 1 µg/ml aprotinin, and 1 µg/ml pepstatin] with 1 mM phenylmethylsulfonyl fluoride (Sigma-Aldrich) (14,39). Lysates were centrifuged at 12,000 x g for 5 min for 4˚C, and the concentration of total protein in the supernatant was quantified by bicinechinonic acid protein assay. Protein samples (20 µg) were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis on 8, 10 or 12% gels, then transferred onto 0.45 µm polyvinylidene fluoride membranes (EMD Millipore, Billerica, MA, USA). The membranes were blocked with 5% (v/v) nonfat dried milk in Tris-buffered saline containing 0.05% Tween-20 (TBS-T) at room temperature for 1 h, then incubated with the primary antibody at 4˚C overnight. GRP78, CHOP and PERK antibodies were used at a dilution of 1:1,000, β-actin antibody at 1:2,000, and VCAM-1, p-PERK, JNK, p-JNK and caspase-3 antibodies at 1:200. Membranes were then washed 3 times in TBS-T, and incubated in HRP-conjugated secondary antibodies (1:4,000) for 1 h at 37˚C. Protein complexes were detected using enhanced chemiluminescence western blotting detection reagents (MAC Gene Technology Ltd.). Digital images of the blots were analyzed using Image Pro Plus 6.0 software (Media Cybernetics, Inc., Rockville, MD, USA).

**Statistical analysis.** All experimental data are presented as the mean ± standard deviation of at least three independent experiments. One-way analysis of variance was performed using SPSS 13.0 for Windows (SPSS, Inc., Chicago, IL, USA) to compare variances. If variances were equal, Bonferroni multiple comparison tests were performed using with SPSS 13.0; otherwise, Tamhane's T2 test was performed by SPSS 13.0. P<0.05 was considered to indicate a statistically significant difference.
Results

Effect of quercetin on the viability of HUVECs treated with high-dose glucosamine. Exposure of HUVECs to an ER stress inducer, tunicamycin, and 15 mM glucosamine resulted in a significant decrease in cell viability compared with the vehicle control (P<0.001 for 5 µg/ml tunicamycin group and HG, 15 mM glucosamine).

Cell viability was restored in cells cultured in 15 mM glucosamine following treatment with 20 or 50 µM quercetin, with no significant changes detected compared with vehicle (Fig. 1). Cell viability compared with the vehicle control was not significantly altered in cells treated with 50 µM quercetin, whether cultured with or without 15 mM glucosamine (Fig. 1).

Effect of quercetin on the apoptosis of HUVECs treated with high-dose glucosamine. Fig. 2 demonstrates TUNEL-positive HUVECs (strong red fluorescence) that are undergoing apoptosis. There was no significant difference observed between the vehicle and mannitol-treated groups (Fig. 2). Treatment with 15 mM glucosamine resulted in increased apoptosis compared with the vehicle group (P<0.001; Fig. 2). However, a dose-dependent effect was observed in cells also treated with quercetin, with no significant difference in the number of TUNEL-positive cells when treated with 10 and 20 µM quercetin compared with the vehicle control (Fig. 2).

Effect of quercetin on expression of markers of endothelial dysfunction in HUVECs treated with high-dose glucosamine. Stimulation of HUVECs with 15 mM glucosamine resulted in significantly increased expression of ICAM-1 and ET-1 compared with the vehicle control group (P=0.009 for ICAM-1 and P=0.049 for ET-1, respectively; Fig. 3A and B, respectively). Following quercetin treatment, ICAM-1 expression was decreased significantly at all concentrations of quercetin treatment compared with the HG group (P=0.016, P<0.001 and P=0.022 for 5, 10, 20 µM quercetin, respectively; Fig. 3A), and demonstrated no significant difference compared with the vehicle control.
ET-1 expression was significantly decreased compared with the HG group at 20 µM (P=0.030; Fig. 3B), and demonstrated no significant difference compared with the vehicle control at all concentrations of quercetin treatment (Fig. 3B). No effect on VCAM-1 expression was observed in response to treatment with 15 mM glucosamine or quercetin compared with the vehicle control (Fig. 3C).

Effects of quercetin on the expression of inflammation, apoptosis and ER stress markers in HUVECs treated with high-dose glucosamine. Inflammation, apoptosis and ER stress in HUVECs was evaluated by assessment of the protein expression levels of VCAM-1, CHOP, GRP78, JNK, PERK, and caspase-3. No significant differences were observed between the vehicle and mannitol-treated groups.
with respect to these parameters (Fig. 4). Protein expression levels of VCAM-1, CHOP and GRP78 were increased in cells cultured in 15 mM glucosamine compared with the vehicle control group (P<0.05; Fig. 4). Furthermore, the ratios of p-JNK/JNK, p-PERK/PERK and cleaved caspase-3 at 20, 17 and 11 kDa/pro-caspase-3 were also significantly higher in cells cultured in 15 mM glucosamine compared with the vehicle control group (P<0.05; Fig. 4). Treatment with quercetin (particularly 10 and 20 µM) significantly attenuated this effect compared with cells cultured in 15 mM glucosamine (P<0.05 following treatment with 20 µM quercetin; Fig. 4), suggesting that quercetin may protect against ER stress, thus suppressing glucosamine-induced inflammation and apoptosis in HUVECs.

**Discussion**

To the best of our knowledge, the present study is the first to report that quercetin ameliorates glucosamine-induced apoptosis and inflammation of HUVECs *in vitro*. Furthermore, these effects may be partially attributed to the alleviation of ER stress pathways in HUVECs.

Quercetin absorption depends on its form, and its solubility in the vehicle used for administration (42). Quercetin glycoside is the predominant form of quercetin, and the majority of the quercetin metabolites in plasma are sulfate/glucuronide conjugates of quercetin (43). In a study investigating the fate of quercetin, [14C]-quercetin was administered orally (100 mg, 330 µM) to healthy volunteers (44). The study observed that the oral absorption ranged from 36.4 to 53%, and the biological half-life was 20-72 h. The maximum concentration of quercetin in the plasma of mice has been demonstrated to be 27.6 µM (31), however, in certain population studies the highest concentration of quercetin in plasma was <5 µM (23,38). Further studies are, therefore, required to determine the pharmacokinetics of quercetin.

The effect of glucosamine on diabetic AS and osteoarthritis management remains controversial. At a concentration of 5 mM *in vitro*, glucosamine has been demonstrated to induce insulin resistance (10) and promote pro-apoptotic and pro-inflammatory factors in HUVECs at a concentration of 7.5 mM (45). However, another study showed that glucosamine, up to 20 mM, fully protected the chondrocytes from IL-1-induced expression of inflammatory cytokines (46). *In vivo* studies have demonstrated glucosamine to be both pro- (11) and anti-atherosclerotic (12). In the present study, glucosamine induced apoptosis in HUVECs at a concentration of 15 mM, while no significant difference in apoptosis was observed with 15 mM mannitol, an osmolarity control, compared with vehicle. As demonstrated in a previous study, quercetin could effectively inhibit the apoptosis of HUVECs induced by tunicamycin (34). The present study demonstrated that in HUVECs cultured in 15 mM glucosamine, 24 h treatment with quercetin significantly reduces apoptosis compared with untreated cells. These results demonstrate that quercetin can prevent glucosamine-induced apoptosis, and may represent a novel approach to inhibition of vascular endothelial cell apoptosis in diabetic AS.

Inflammation is an important in the process of AS (47,48). Hyperglycemia induces ICAM-1 and VCAM-1 expression in HUVECs (49); however, Azcutia *et al* (50) suggested that high levels of extracellular D-glucose alone are not sufficient to promote vascular inflammation. The present study demonstrated that glucosamine significantly elevates ICAM-1 and VCAM-1 protein expression levels. Quercetin has previously been demonstrated to be a powerful anti-inflammatory agent to alleviate AS *in vivo* (31) and *in vitro* (30,51). The present study indicated that protein expression levels of ICAM-1 and VCAM-1 were significantly reduced following treatment with quercetin. These data, therefore, suggest that vascular inflammation may be partially due to the elevated glucosamine levels present in patients with diabetes; quercetin may represent an effective, novel therapy to resist HUVECs glucosamine-induced inflammation.

The HBP is associated with vasodilation and the ET-1-induced vasconstriction response (52,53). HBP activated by excess glucosamine causes endothelial nitric oxide synthase uncoupling to decrease nitric oxide production in isolated mouse aortas, this effect impaired endothelium-dependent relaxations finally (52). Furthermore, ET-1 increases glycosylation with β-N-acetylglicosamine in vascular smooth muscle cells, which increases vascular contractile responses (53). Both decreased vasodilation, and increased vasconstriction associated with the HBP, could result in vascular endothelial dysfunction. ET-1 induced glucose uptake dose dependently in neonatal rat cardiomyocytes when cells were cultured in normal medium. However, when cells were cultured in 15 mM glucosamine based on 5 mM glucose, the increased glucose-uptake effect of ET-1 on glucose-uptake was completely abolished (54). The present study demonstrated a significant increase in ET-1 protein expression in cells cultured in 15 mM glucosamine treatment, compared with vehicle. However, treatment of glucosamine-stimulated cells with quercetin, resulted in a significant decrease in ET-1 expression. This suggests that quercetin intervention may improve vascular endothelial dysfunction.

ER stress results in dissociation of GRP78, an ER chaperone protein, from trans-ER-membrane factors, including activating transcriptional factor-6, PERK and inositol requiring enzyme-1. This results in their activation, and the subsequent activation of CHOP, JNK or caspase cascades, causing apoptosis and inflammation (6). Glucosamine has previously been demonstrated to significantly increase GRP78 levels in HUVECs (45). Qiu *et al* (55) demonstrated that glucosamine-induced ER stress was associated with increased phosphorylation of PERK. JNK is the down-stream effector of ER stress, responsible for induction of apoptosis (56); it also mediates the process between ER stress and inflammation (19). Suganya *et al* (34) demonstrated that pre-treatment of tunicamycin-stimulated HUVECs with 25 and 50 µM quercetin could modulate GRP78 and CHOP levels, reduce expression of B cell lymphoma 2 apoptosis regulator (Bcl-2), and anti-apoptosis Bcl-2 associated protein X apoptosis regulator (Bax) and prevent apoptosis, therefore demonstrating the potential of quercetin to combat ER stress. In the present study, the effects of quercetin that contribute to reduced vascular endothelial cell injury were hypothesized to have a common upstream target: ER stress. This was confirmed by assessment of GRP78 and p-PERK protein expression levels in HUVECs; elevated
expression of GRP78 and an increased p-PERK/PERK ratio were induced by supplementation with 15 mM glucosamine. Significant increases in CHOP, p-JNK and cleaved caspase-3 expression levels were also observed in cells cultured in 15 mM glucosamine. Treatment with quercetin reduced the expression of GRP78, p-PERK, CHOP, cleaved caspase-3 and p-JNK in glucosamine-supplemented cells, thus restoring ER homeostasis.

Tunicamycin is a typical ER stress inducer by interfering with N-linked protein glycosylation in ER (57). Whether tunicamycin can abolish the beneficial effects of quercetin on glucosamine-induced HUVECs damage remains to be investigate. It can further confirm that the ER stress pathway is involved in the beneficial effects of quercetin on glucosamine-induced HUVECs damage. Although animal studies have demonstrated a maximum concentration of 27.6 µM quercetin in mouse plasma (31), human clinical studies have observed a maximum plasma concentration of 5 µM (23,38). In the present study, 20 µM quercetin was identified as the concentration at which positive effects were observable. As this is likely to be a difficult concentration to achieve in the human diet, further experiments are required to determine a safe and effective quercetin dose in vivo. In addition, further experiments using animal models of diabetic AS and human clinical studies will be essential to further understand the mechanism of action.

In conclusion, the present study suggests that quercetin suppresses the glucosamine-induced inflammatory response and apoptosis in HUVECs, in vitro, and that this effect may be partially due to the inhibition of ER stress. The ER-CHOP and ER-JNK pathways may be involved in the protective effects of quercetin against glucosamine-induced HUVEC injury, and PERK may be a critical factor in the molecular mechanism involved in its protective effects. These results provide further evidence that quercetin may be a potential therapeutic agent for diabetic AS, and ER stress may be one of the possible targets.

Acknowledgements

The present study was supported by a research grant from the National Natural Science Foundation of China (grant no. 81172652).

References


